应世生物科技（上海）有限公司 INXMED Mediaroom

InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2024-11-21 15:09 1031

InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC

NANJING, China, Nov. 7, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compan...

2024-11-08 10:40 1324

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedica...

2023-12-20 09:00 1667

InxMed Releases Data Demonstrating Ifebemtinib (IN10018) Trending Toward Survival Benefit at ESMO 2023

NANJING, China, Oct 22, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compan...

2023-10-23 08:00 1673

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

NANJING, China, Oct. 18, 2023 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2023-10-19 08:00 1542

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedica...

2023-08-30 11:00 1815

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-10-18 08:00 1140

InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

NANJING, China, Sept. 7, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-09-08 08:00 1656

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer

NANJING, China, May 29, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-05-30 08:10 1854

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company...

2022-05-09 08:04 1798

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer

NANJING, China, April 13, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN0018, its focal a...

2022-04-14 08:00 1991

InxMed Raised $50 million in Series B Financing to Advance Innovative Therapies to Drug-resistance Cancers

NANJING, China, March 3, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology compa...

2022-03-04 08:00 1821

InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer

NANJING, China, Aug. 15, 2021 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), ...

2021-08-16 09:31 1480

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clin...

2021-06-25 15:06 1519

InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities

NANJING, China, Sept. 4 2020 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a ...

2020-09-04 11:24 3623

InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities

InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting

SHANGHAI, June 24, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clin...

2020-06-24 08:41 2116

InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States

SHANGHAI, March 17, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a cli...

2020-03-17 09:05 2989

InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab

SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd., a clinical stage biotech compa...

2020-01-07 08:25 3385

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for IN10018

BEIJING, Dec. 20, 2019 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clini...

2019-12-20 18:21 2391

Latest News